Improved margins and rising partner revenue highlight early impact of the company’s revised global model.
Amarin Corporation plc (NASDAQ:AMRN) released its earnings report for the first quarter of 2026, showing revenue growth, significantly reduced operating expenses, and narrowing losses—developments that may signal early traction from its revamped global business strategy.
The company reported total net revenue of $45.1 million, up 7% year over year, while operating expenses fell 31%, leading to a 32% improvement in operating loss.
Key Investor Takeaways
- The earnings report showed a 7% revenue increase, supported by partner-driven sales and licensing growth
- Amarin Corporation plc (AMRN) reduced operating expenses by 31%, reflecting restructuring and cost control efforts
- Losses narrowed significantly, with operating loss improving 32% and net loss declining year over year
- Growth in licensing and royalties revenue (+84%) signals increasing reliance on international partners
- Management expects to remain cash flow positive in 2026, with $307.8 million in cash and no debt
Press Release Overview
Amarin reported Q1 2026 total net revenue of $45.1 million, compared to $42.0 million in the same period last year. Product revenue reached $43.3 million, while licensing and royalty revenue rose sharply to $1.8 million.
U.S. revenue remained stable at $35.6 million, supported by increased prescription volumes tied to regained exclusivity with a major pharmacy benefit manager. European revenue declined slightly year over year due to the transition to a partner-based model, while rest-of-world revenue increased.
Operating expenses fell to $29.1 million from $41.9 million, primarily due to reduced SG&A costs following a global restructuring initiative. Excluding restructuring charges, expenses declined 38%.
The company reported an operating loss of $11.3 million, compared to $16.8 million a year earlier, while net loss improved to $10.5 million from $15.7 million.
Cash and investments rose to $307.8 million, and the company remains debt free.
Management highlighted continued progress in its international strategy, including growing demand for VAZKEPA in Europe through its partnership with Recordati, which has launched the product in 10 countries and plans further expansion.
“Our results for Q1 2026 reflected the early yet measurable progress generated by our refined global business model which we adopted in mid-2025,” said CEO Aaron Berg.
The company also noted that U.S. prescription data showed a 17% increase in VASCEPA-branded prescriptions year over year, with expectations for stable volumes through 2026.
Why This Matters for Investors
The earnings report suggests that Amarin’s transition to a leaner, partner-driven business model may be beginning to show results.
Lower operating expenses and improved margins indicate that restructuring efforts are having a measurable financial impact, which could improve the company’s sustainability profile.
At the same time, the shift toward licensing and international partnerships—evidenced by strong growth in royalty revenue—may reduce reliance on direct commercial operations while expanding global reach.
Stable U.S. performance despite generic competition and rising prescription volumes may also signal resilience in its core market.
However, variability in European sales and dependence on partners could introduce new uncertainties around revenue consistency.
What to Watch Next
- Progress in European expansion through the Recordati partnership
- Trends in VASCEPA prescription growth in the U.S.
- Execution of cost savings and confirmation of full-year cash flow positivity
- Updates on strategic initiatives with financial advisor Barclays
Conclusion
Amarin’s latest earnings report highlights improving financial discipline and early momentum from its revised business model. While the company is still operating at a loss, narrowing deficits, rising partner revenue, and stable U.S. performance suggest a potential shift in its operating trajectory—one that investors will continue to monitor closely.